PMID: 7537527Mar 1, 1995Paper

Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/beta-thalassaemia

British Journal of Haematology
E VoskaridouD Loukopoulos

Abstract

Hydroxyurea (HU), a widely used cytostatic, has been given over a long period of time to 14 adult Caucasian compound heterozygotes for beta s and various beta-thalassaemia genes. All patients had severe pain crises and other complications prior to receiving the drug. After 4-8 weeks on high 'sub-toxic' doses of HU all patients responded with a multifold increase of fetal haemoglobin (HbF) and a marked increase of MCV and MCH; they also felt significantly better and ceased having pains or other complaints. Haematological toxicity was minimal and rapidly reversible. Follow-up of the patients has now exceeded 100 weeks and goes up to 180 weeks in two of them. Pain crises have never recurred. Maintenance of high levels of HBF requires continuous administration of high doses of HU; whenever the latter were decrease in various attempts to avoid potential long-term toxicity, the observed changes gradually faded. The effect of HU in HbS/beta-thalassaemia may be better than that reported for homozygous HbS disease because the synthesized gamma-chains not only inhibit the sickling process but they also neutralize the noxious effects of the excess alpha-chains and cut down the ineffective erythropoiesis of the patients.

References

Feb 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·R L NagelK Matsutomo
Apr 12, 1990·The New England Journal of Medicine·G P RodgersA W Nienhuis
Dec 19, 1985·The New England Journal of Medicine·R VeithG Stamatoyannopoulos
Jan 14, 1988·The New England Journal of Medicine·C T NoguchiA N Schechter
Oct 1, 1989·American Journal of Hematology·S K BallasS Charache
Apr 5, 1984·The New England Journal of Medicine·N L LetvinD G Nathan
Aug 1, 1984·The Journal of Clinical Investigation·O S PlattD G Nathan

❮ Previous
Next ❯

Citations

Jul 1, 1996·Journal of Clinical Pharmacology·L R Brettman, P R Chaturvedi
Sep 30, 1998·British Journal of Haematology·I PapassotiriouC Poyart
Sep 12, 2001·Medicine·M H Steinberg, G P Rodgers
Oct 3, 2002·Annual Review of Medicine·Martin H Steinberg, Carlo Brugnara
Apr 9, 2005·International Journal of Cancer. Journal International Du Cancer·Naohiro WakisakaJoseph S Pagano
Jul 14, 2005·Journal of Pediatric Hematology/oncology·Mehran KarimiMajid Yavarian
Mar 19, 2019·The Cochrane Database of Systematic Reviews·Saqib H AnsariTahir S Shamsi
Jul 21, 1998·Annals of the New York Academy of Sciences·D LoukopoulosN Pavlides
Jan 25, 2003·British Journal of Haematology·Christina Halsey, Irene A Roberts
Nov 12, 1996·Proceedings of the National Academy of Sciences of the United States of America·H SierakowskaR Kole
Oct 1, 1995·British Journal of Haematology·G P Rodgers, E A Rachmilewitz
Jan 24, 1998·Critical Reviews in Clinical Laboratory Sciences·T SzekeresH L Elford
Jun 6, 1996·HEC Forum : an Interdisciplinary Journal on Hospitals' Ethical and Legal Issues·A Catlin
Jan 12, 1999·American Journal of Hematology·M M UddenD A Sears
Apr 1, 1999·The New England Journal of Medicine·M H Steinberg
Feb 6, 2007·American Journal of Hematology·David MasielloDavid H K Chui
Jun 18, 2014·Expert Opinion on Biological Therapy·Alessia Finotti, Roberto Gambari
Oct 16, 1999·British Journal of Haematology·O Castro
Mar 19, 2003·Blood Reviews·Sally C Davies, Annette Gilmore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.